Ongoing Trials Looking at Combinations in Bladder Cancer

November 19, 2018
Arjun V. Balar, MD

Arjun V. Balar, MD, discusses some combinations currently being investigated in clinical trials for patients with bladder cancer.

Arjun V. Balar, MD, assistant professor in the Department of Medicine and director of the genitourinary medical oncology program at NYU Langone’s Perlmutter Cancer Center, discusses some combinations currently being investigated in clinical trials for patients with bladder cancer.

According to Balar, CTLA-4 blockade is being tested in combination with PD-1 blockade. The PD-1 pathway can play an important role in the treatment of bladder cancer, but it still needs to be tested further. This strategy is being investigated in both the CheckMate901 trial and the DANUBE trial.